Research
Hormonal
Demographic disparities exist in weight loss response to GLP-1RAs, with White and female patients more likely to be high responders, while Black and Hispanic patients are more likely to be minimal responders.
Be aware that real-world data shows White and female patients are more likely to achieve high weight loss with GLP-1RAs, while Black and Hispanic patients are more likely to have minimal weight loss. This highlights the need for personalized treatment strategies.
GoodQualifiesMEDIUM confidence
White patients were more represented among high responders, whereas Black and Hispanic patients were more represented among the minimal weight loss group.
Why this rating
Large cohort, but observational data cannot determine causality of demographic disparities.
Source
Weight Loss Dynamics and Health Burden Changes with Tirzepatide versus Semaglutide
AJ Venkatakrishnan et al. · medRxiv · 2025
DOI 10.64898/2025.11.30.25341294
preprint · n=20678Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →